HomeIRWD • NASDAQ
Ironwood Pharmaceuticals, Inc.
$1.49
1.32%
-0.020 Today
After Hours:
$1.49
(0.00%)0.00
Closed: Mar 14, 4:20:00 PM UTC-4 · USD · NASDAQ · Disclaimer
Market news
Financials
Income Statement
050M100M
Revenue
Net Income
Revenue
Net income
(USD)Dec 2024Y/Y change
Revenue
90.55M-22.98%
Operating expense
33.33M-29.04%
Net income
3.19M393.38%
Net profit margin
3.52482.61%
Earnings per share
0.02
EBITDA
34.20M7.80%
Effective tax rate
87.28%
0200M400M600M800M
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD)Dec 2024Y/Y change
Cash and short-term investments
88.56M-3.90%
Total assets
351.30M-25.43%
Total liabilities
652.55M-20.17%
Total equity
-301.25M
Shares outstanding
159.45M
Price to book
-0.80
Return on assets
22.47%
Return on capital
27.66%
020M
Net Change in Cash
Net change in cash
(USD)Dec 2024Y/Y change
Net income
3.19M393.38%
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
StockUS listed securityUS headquartered
Previous close
$1.51
Day range
$1.47 - $1.55
Year range
$1.34 - $9.23
Market cap
238.44M USD
Avg Volume
4.28M
P/E ratio
131.51
Dividend yield
-
Primary exchange
NASDAQ
About
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. Wikipedia
Founded
1998
Employees
267
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Main menu
Google apps